A Placebo-Controlled Double-Blind Multicenter Study of Celiprolol in the Treatment of Mild and Moderate Hypertension

Capone, P.; Mayol, Renato

doi:10.1097/00005344-198608004-00027

Cited by 15 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Extensive clinical trials have established the efficacy of celiprolol, a cardioselective beta blocker with vasodilating activity, in the treatment of hypertension and angina [1,2,[21][22][23][24][25][26][27]. The present paper summarized a number of evaluations of the effects of celiprolol in the elderly: its pharmacokinetic and rectabolic disposition, comparative efficacy with placebo and other beta blockers, overall safety and therapeutic ratio, and postmarketing experience.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of celiprolol, a new cardioselective beta1-adrenergic blocker with vasodilating properties, in the treatment of mild to moderate hypertension in the elderly

Kd¹

1991

Cardiovasc Drug Ther

View full text Add to dashboard Cite

Celiprolol hydrochloride is a cardioselective beta 1-adrenergic antagonist with partial agonist activity. The studies discussed were designed to assess celiprolol's pharmacokinetic disposition, its efficacy versus placebo and other beta blockers, its relative safety profile, and its therapeutic ratio in the elderly population. The results of a postmarketing surveillance study are also presented. Pharmacokinetic results indicate good dose-related bioavailability in the elderly, no accumulation on multiple dosing, and pharmacokinetics equivalent to those in a younger age group. Celiprolol effectively lowers blood pressure in elderly patients with mild to moderate hypertension, resulting in reductions of 12-15 mmHg and 8-11 mmHg in systolic and diastolic blood pressures, respectively. A clinically insignificant reduction in resting pulse rate is observed with celiprolol treatment. Its adverse experience profile is equivalent to that of placebo, and the incidence of beta-blocker-associated side effects is lower compared with that of atenolol and propranolol. Celiprolol also effectively controlled hypertension in the elderly in the postmarking surveillance study. Collectively, the results of these studies demonstrate that the pharmacokinetics and efficacy of celiprolol in the treatment of mild to moderate hypertension are equivalent in younger and older populations, and that the therapeutic ratio (i.e., efficacy/safety) of celiprolol is superior to that of atenolol and propranolol in the elderly.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Once daily administration of celiprolol 200-600 mg to hypertensive patients decreased both standing and supine blood pressure in a dose-related manner [21][22][23][24][25]. In addition to its effectiveness in the treatment of hypertension and angina pectoris [26,27], celiprolol has a favorable effect on plasma lipids [28].…”

mentioning

confidence: 99%

Evaluation of celiprolol, a new cardioselective beta1-adrenergic blocker with vasodilating properties, in the treatment of mild to moderate hypertension in the elderly

Kd¹

1991

Cardiovasc Drug Ther

View full text Add to dashboard Cite

show abstract

“…In one such study the mean blood pressure in the 114 celiprolol-treated patients fell over a 6-week period from 165/103 mmHg to 149/92 mmHg, in comparison to a mean change from 162/103 mmHg to 157/97mmHg in the 84~patient placebo group [8]. In one such study the mean blood pressure in the 114 celiprolol-treated patients fell over a 6-week period from 165/103 mmHg to 149/92 mmHg, in comparison to a mean change from 162/103 mmHg to 157/97mmHg in the 84~patient placebo group [8].…”

Section: R J Norrkmentioning

confidence: 99%

Efficacy of celiprolol in hypertension and angina pectoris

Norris¹

1991

Cardiovasc Drug Ther

View full text Add to dashboard Cite

“…Celiprolol has only minor effects on resting heart rate or mean arterial pressure in normotensive individuals (Dovard et al 1989;Kawakubo et al 1990). In hypertensive patients, effective normalisation of BP is achieved without bradycardia (Capone & Mayol 1986;Rodriguez et al 1992;Rosenthal et al 1985a;Stumpe et al 1985;Taylor et al 1986). …”

Section: Effects On Heart Ratementioning

confidence: 99%

A Risk-Benefit Assessment of Celiprolol in the Treatment of Cardiovascular Disease

Kendall

Rajman

1994

Drug Safety

View full text Add to dashboard Cite

Celiprolol is a third-generation beta-adrenoceptor blocker with selective beta 1-antagonist, partial beta 2-agonist and mild alpha 2-antagonist actions. It seems to be as effective as other beta-blockers in the treatment of hypertension and angina pectoris. beta-Blockers have many cardioprotective effects and have been shown to reduce the morbidity and mortality from coronary artery disease in a number of trials. However, there is no good clinical evidence that celiprolol itself has specific cardioprotective properties other than those attributable to this class of drugs. Because of its pharmacological profile, celiprolol is less likely to cause bradycardia, deterioration in cardiac function and other adverse effects mainly caused by beta 2-blockade. Unlike most other beta-blockers, celiprolol has no adverse effects on plasma lipids. It seems to be well tolerated in diabetic patients and patients with renal dysfunction.

show abstract

A Placebo-Controlled Double-Blind Multicenter Study of Celiprolol in the Treatment of Mild and Moderate Hypertension

Cited by 15 publications

References 0 publications

Evaluation of celiprolol, a new cardioselective beta1-adrenergic blocker with vasodilating properties, in the treatment of mild to moderate hypertension in the elderly

Evaluation of celiprolol, a new cardioselective beta1-adrenergic blocker with vasodilating properties, in the treatment of mild to moderate hypertension in the elderly

Efficacy of celiprolol in hypertension and angina pectoris

A Risk-Benefit Assessment of Celiprolol in the Treatment of Cardiovascular Disease

Contact Info

Product

Resources

About